New and Experimental Treatments of Cloasma and Other Hypermelanoses

Dermatologic Clinics

Volumn 25, Issue 3, 2007, Pages 353-362

  Picardo, Mauro ^a   Carrera, Manuela ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYACID; 4 S CYSTEAMINYLPHENOL; ADAPALENE; ALOESIN; ALPHA TOCOPHEROL; ALPHA TOCOPHERYL FERULATE; ARBUTIN; ASCORBIC ACID; AZELAIC ACID; CORTICOSTEROID; DEOXYARBUTIN; DERMATOLOGICAL AGENT; DEXAMETHASONE; ELLAGIC ACID; FLAVONOID; FLUOCINOLONE ACETONIDE; GALLIC ACID; GENTISIC ACID; GLABRIDIN; GLYCOLIC ACID; HYDROQUINONE; KOJIC ACID; LIQUIRITIN; MEQUINOL; MONOBENZONE; N ACETYL 4 S CYSTEAMINYLPHENOL; OXYRESVERATROL; RETINOIC ACID; SUNSCREEN; UNCLASSIFIED DRUG;

ACNE; BURNING SENSATION; CHLOASMA; CLINICAL TRIAL; CONTACT DERMATITIS; DEPIGMENTATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FACE ERYTHEMA; HAIR GROWTH; HUMAN; HYPERPIGMENTATION; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRRITANT DERMATITIS; LENTIGO; LEUKOMELANODERMA EN CONFETTI; MELANOSIS; NAIL COLOR DEFECT; NAIL DISCOLORATION; NONHUMAN; OCHRONOSIS; PERIORAL DERMATITIS; PIGMENT DISORDER; PRIORITY JOURNAL; REVIEW; ROSACEA; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SKIN IRRITATION; TELANGIECTASIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

CHEMEXFOLIATION; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FLAVONOIDS; GLUCOCORTICOIDS; HUMANS; HYDROQUINONES; HYDROXYBENZOIC ACIDS; HYPERPIGMENTATION; LASERS; MELANOSIS; RETINOIDS; TRETINOIN;

EID: 34447643206     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.04.012     Document Type: Review

References (49)

1. Kligman A.M., and Willis I. A new formula for depigmenting human skin. Arch Dermatol 111 1 (1975) 40-48
2. Torok H., Taylor S., Baumann L., et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol 4 5 (2005) 592-597
3. Taylor S.C., Torok H., Jones T., et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 72 1 (2003) 67-72
4. Grimes P., Kelly A.P., Torok H., et al. Community-based trial of triple-combination agent for the treatment of facial melasma. Cutis 77 3 (2006) 177-184
5. Torok H.M. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol 7 4 (2006) 223-230
6. Guevara I.L., and Pandya A.G. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 42 12 (2003) 966-972
7. Zawar V.P., and Mhaskar S.T. Exogenous ochronosis following hydroquinone for melasma. J Cosmet Dermatol 3 4 (2004) 234-236
8. Kooyers T.J., and Westerhof W. Toxicology and health risks of hydroquinone in skin lightening formulations. J Eur Acad Dermatol Venereol 20 7 (2006) 777-780
9. Nordlund J.J., Grimes P.E., and Ortonne J.P.J. The safety of hydroquinone. J Eur Acad Dermatol Venereol 20 7 (2006) 781-787
10. Halder R.M., and Richards G.M. Management of dyschromias in ethnic skin. Dermatol Ther 17 2 (2004) 151-157
11. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 127 10 (1991) 1528-1534
12. Fleischer Jr. A.B., Schwartzel E.H., Colby S.I., et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 42 3 (2000) 459-467
13. Draelos Z.D. The combination of 2% 4-hydroxyanisole (mequinol) and 0,01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol 5 3 (2006) 239-244
14. Sugimoto K., Nomura K., Nishimura T., et al. Syntheses of alpha-arbutin-alpha-glycosides and their inhibitory effects on human tyrosinase. J Biosci Bioeng 99 3 (2005) 272-276
15. Boissy R.E., Visscher M., and DeLong M.A. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 14 8 (2005) 601-608
16. Verallo-Rowell V.M., Verallo V., Graupe K., et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 143 (1989) 58-61
17. Balina L.M., and Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 30 12 (1991) 893-895
18. Zaumseil RP, Graupe K. Topical azelaic acid in the treatment of melasma: pharmacological and clinical considerations. In: Melasma. New approaches to therapy. London: Martin-Dunitz; 1995. p. 19-41.
19. Garcia A., and Fulton Jr. J.E. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 22 5 (1996) 443-447
20. Takizawa T., Mitsumori K., Tamura T., et al. Hepatocellular tumor induction in heterozygous p53-deficient CBA mice by a 26-week dietary administration of kojic acid. Toxicol Sci 73 2 (2003) 287-293 [Epub 2003 Apr 15]
21. Yokota T., Nishio H., Kubota Y., et al. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 11 6 (1998) 355-361
22. Amer M., and Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 39 4 (2000) 299-301
23. Solano F., Briganti S., Picardo M., et al. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 19 6 (2006) 550-571
24. Shin N.H., Ryu S.Y., Choi E.J., et al. Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom tyrosinase. Biochem Biophys Res Commun (1998) 243(3):801-3
25. Shimogaki H., Tanaka Y., Tamai H., et al. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int J Cosmet Sci 22 4 (2000) 291-303
26. Jones K., Hughes J., Hong M., et al. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res 15 5 (2002) 335-340
27. Usuki A., Ohashi A., Sato H., et al. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol 2 Suppl 12 (2003) 43-50
28. Funasaka Y., Komoto M., and Ichihashi M. Depigmenting effect of alpha-tocopheryl ferulate on normal human melanocytes. Pigment Cell Res 8 Suppl 13 (2000) 170-174
29. Espinal-Perez L.E., Moncada B., and Castanedo-Cazares J.P. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol 43 8 (2004) 604-607
30. Menter A. Rationale for the use of topical corticosteroids in melasma. J Drugs Dermatol 3 2 (2004) 169-174
31. Ortonne J.P. Retinoid therapy of pigmentary disorders. Dermatol Ther 19 5 (2006) 280-288
32. Winhoven S.M., Ahmed I., Owen C.M., et al. Postinflammatory hyperpigmentation in an Asian patient: a dramatic response to oral isotretinoin (13-cis-retinoic acid). Br J Dermatol 152 2 (2005) 368-369
33. Saliou C., Kitazawa M., McLaughlin L., et al. Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line. Free Radic Biol Med 26 1-2 (1999) 174-183
34. Seiberg M., Paine C., Sharlow E., et al. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol 115 2 (2000) 162-167
35. Hakozaki T., Minwalla L., Zhuang J., et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 147 1 (2002) 20-31
36. Otte N., Borelli C., and Korting H.C. Nicotinamide-biologic actions of an emerging cosmetic ingredient. Int J Cosmet Sci 27 (2005) 255-261
37. Hakozaki T., Takiwaki H., Miyamoto K., et al. Ultrasound enhanced skin-lightening effect of vitamin C and niacinamide. Skin Res Technol 12 2 (2006) 105-113
38. Wiechers J.W., Rawlings A.V., Garcia C., et al. A new mechanism of action for skin whitening agents: binding to peroxisome proliferator activated receptor. Int J Cosmet Sci 27 2 (2005) 123-132
39. Javaheri S.M., Handa S., Kaur I., et al. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol 40 5 (2001) 354-357
40. Sharquie K.E., Al-Tikreety M.M., and Al-Mashhadani S.A. Lactic acid as a new therapeutic peeling agent in melasma. Dermatol Surg 31 2 (2005) 149-154
41. Hyo H.A., and Il-hwan K. Whitening effect of salycilic acid peels in Asian patients. Dermatol Surg 32 3 (2006) 372-375
42. Berardesca E., Cameli N., Primavera G., et al. Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. Dermatol Surg 32 4 (2006) 526-531
43. Khunger N., Rashmi S., and Jain R.K. Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients. Dermatol Surg 30 5 (2004) 756-760
44. Chun E.Y., Lee J.B., and Lee K.H. Focal trichloroacetic acid peel method for benign pigmented lesions in dark-skinned patients. Dermatol Surg 30 (2004) 512-516
45. Piamphongsant T. Phenol-castor oil: modified peel for dermal melasma. Dermatol Surg 32 5 (2006) 611-617
46. Lee J.H., Park J.G., Lim S.H., et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg 32 5 (2006) 626-631
47. Alster T.S., and Lupton J.R. Laser therapy for cutaneous hyperpigmentation and pigmented lesions. Dermatol Ther 14 1 (2001) 46-54
48. Jones C.E., and Keyvan N. Laser treatment for pigmented lesions: a review. J Cosmet Dermatol 5 (2006) 9-13
49. Wang C.C., Hui C.Y., Sue Y.M., et al. Intense pulsed light for treatment of refractory melasma in Asian persons. Dermatol Surg 30 (2004) 1196-1200